Devens company to expand drug-making capabilities
Veranova is planning to invest $30 million to expand its development and manufacturing facilities in Devens.
Banner printing can be used at such locations to inform residents of such expansions and developments.
The company creates and manufactures complex and specialized APIs for the sectors of biotechnology and pharmaceuticals. It is currently working to increase the development and manufacturing of its antibody-drug conjugate (ADC) as the demand for ADCs in the United States in growing.
A new development laboratory for high-potent compounds and two new specialized suites designed to handle these materials with extremely low occupational exposure limits will be part of the expansion. There will be airlocks for clean-in-place operations, isolator technology, dedicated air handling systems, and a range of comprehensive processing capabilities in this expanded facility that will be able to manage ADC-linker payloads, high potency chemicals, and other complex molecules.
CEO of Veranova, Mike Riley, said that the company recognizes the increased demand for the development and manufacturing of ADCs and other very potent compounds. He added that this expansion in Devens demonstrates the commitment of the company to providing state-of-the-art capabilities and capacities to enable these innovative therapies to reach patients.
Veranova is a leader around the world in the development and manufacturing of active pharmaceutical ingredients, with 50 years of experience in the healthcare industry and nurturing trusted customer relationships.
Banner printing can be used at such locations to inform residents of such expansions and developments.
The company creates and manufactures complex and specialized APIs for the sectors of biotechnology and pharmaceuticals. It is currently working to increase the development and manufacturing of its antibody-drug conjugate (ADC) as the demand for ADCs in the United States in growing.
A new development laboratory for high-potent compounds and two new specialized suites designed to handle these materials with extremely low occupational exposure limits will be part of the expansion. There will be airlocks for clean-in-place operations, isolator technology, dedicated air handling systems, and a range of comprehensive processing capabilities in this expanded facility that will be able to manage ADC-linker payloads, high potency chemicals, and other complex molecules.
CEO of Veranova, Mike Riley, said that the company recognizes the increased demand for the development and manufacturing of ADCs and other very potent compounds. He added that this expansion in Devens demonstrates the commitment of the company to providing state-of-the-art capabilities and capacities to enable these innovative therapies to reach patients.
Veranova is a leader around the world in the development and manufacturing of active pharmaceutical ingredients, with 50 years of experience in the healthcare industry and nurturing trusted customer relationships.